Centocor, Inc.

MRI data show monoclonal antibody treatment decreases spinal inflammation

Published in Lab Business Week, November 21st, 2004

Results of the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy (ASSERT) trial demonstrated that patients with active ankylosing spondylitis (AS) treated with Remicade (infliximab), had a median decrease of 73% in spinal inflammation activity scores at 24 weeks of treatment, while patients receiving placebo showed no effect as measured by magnetic resonance imaging (MRI).

According to a statement from Centocor, if inflammation persists and is left untreated, loss of spinal mobility and structural damage to the spine may result. The study included the largest number of patients with AS ever evaluated for spinal inflammation using MRI. MRI...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Business Week

Source: Lab Business Week (2004-11-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry